Novo Nordisk and Eli Lilly are unlikely to break a partnership with LifeMD. ... WorkSimpli accounts for 23% of LifeMD’s revenue and has been a relatively stable cash cow for LifeMD.

In this podcast, Motley Fool Chief Investment Officer Andy Cross and contributors Jason Hall and Matt Frankel discuss: Fair ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Elanco, a division of Eli Lilly and Company (NYSE:LLY), announces the addition of Keto-Test® to its current portfolio of productivity products for dairy producers. Keto-Test is a color-changing test ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

Deal would add a potential treatment for cardiovascular disease to Eli Lilly’s portfolio.

Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing ...

Beyond current successes, Eli Lilly is innovating with a potential game-changing oral GLP-1, orforglipron. Read why I ...

South Korea's trade minister Yeo Han-koo will visit the United States from June 22 to 27, the trade ministry said on Saturday ...